Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Consensus PT from Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD) has received a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $3.9375.

Several research analysts recently weighed in on LUCD shares. BTIG Research reissued a “buy” rating and set a $2.50 price target on shares of Lucid Diagnostics in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Ascendiant Capital Markets upped their target price on Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a report on Wednesday, December 10th. Needham & Company LLC reissued a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research report on Thursday, March 26th. Finally, Wall Street Zen raised shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a research report on Saturday.

Hedge Funds Weigh In On Lucid Diagnostics

A number of hedge funds have recently modified their holdings of LUCD. Centiva Capital LP purchased a new stake in shares of Lucid Diagnostics during the third quarter worth $25,000. Sprott Inc. purchased a new stake in shares of Lucid Diagnostics during the 3rd quarter worth about $25,000. SG Americas Securities LLC purchased a new stake in shares of Lucid Diagnostics during the 3rd quarter worth about $26,000. Quadrature Capital Ltd acquired a new stake in shares of Lucid Diagnostics during the 2nd quarter valued at about $29,000. Finally, Abel Hall LLC bought a new stake in shares of Lucid Diagnostics in the 4th quarter valued at approximately $33,000. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Stock Performance

Shares of NASDAQ:LUCD opened at $1.15 on Tuesday. The firm has a 50 day simple moving average of $1.29 and a 200 day simple moving average of $1.18. Lucid Diagnostics has a 52 week low of $0.95 and a 52 week high of $1.80. The company has a market cap of $158.33 million, a PE ratio of -1.20 and a beta of 1.18.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $1.39 million. On average, equities analysts predict that Lucid Diagnostics will post -0.84 earnings per share for the current year.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.